AlphAIalphai — Financial news for AI agents
GlobeNewswireNOV 73 min read$XLO

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden ...

Original reporting
GlobeNewswire · Xilio Therapeutics, Inc.
Published Nov 7, 2025, 2:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 7, 2025, 2:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting — source image
Source · www.globenewswire.com
Decision brief

The 30-second read

$XLOBullishMed
01

Why it matters

The positive Phase 2 data could accelerate clinical development and valuation.

02

Market read

The news is highly relevant to biotech investors, especially those focused on immunotherapy and colorectal cancer treatments.

03

What to watch

Potential delays in further trial phases or regulatory hurdles could negate initial enthusiasm.

Timing: Immediate, as the news is recent and pertains to ongoing clinical developments.

Background

Xilio Therapeutics is advancing in immuno-oncology with Vilastobart, a novel therapy targeting MSS mCRC.

Company-level read

Ticker impact

$XLOBullishHigh confidence
Context

High relevance due to direct mention in the news about a clinical trial result impacting biotech sector.

Expected impact

Moderate upward movement expected within 1-3 trading sessions, approximately 5-10%.

Evidence & confidence

The announcement of promising Phase 2 data in a relevant indication can boost stock sentiment, especially if the data addresses previous concerns or unmet needs.

Market effects

Sector

Potential positive sentiment for biotech and immunotherapy sectors due to promising clinical data.

Regional

Limited regional impact; primarily relevant to US biotech markets.

Global

Moderate; advances in immunotherapy can influence global biotech investment trends.

Counterpoint

What could challenge this read

The positive data may already be priced in, and any overhyped expectations could lead to short-term correction.

Key entities

  • Company
    Xilio Therapeutics

    Biotech firm focusing on immuno-oncology therapies.

  • Drug Candidate
    Vilastobart

    Therapeutic agent showing promising results in MSS mCRC patients.

Read at source← All news

Related articles

AUG 12
$XLOMed

Xilio Therapeutics, Inc. (XLO): Results of Operations and Financial Condition

Xilio Therapeutics, Inc. (XLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 xlo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancin

SEC EDGAR 8-K6 min
AUG 12
$STTKMed

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.

investing.com4 min
AUG 12
$FGLMed

Founder Group Limited Secures Second Aquaculture Contract, a US$1.4 million 1.78 MW rooftop system for a Kedah shrimp Farm

Founder Group Limited (NASDAQ: FGL) said its subsidiary Founder Energy Sdn Bhd signed a turn-key EPCC contract for a 1.78 MW-peak rooftop solar system for a shrimp farming and processing facility in Ayer Hitam, Kedah. The contract is valued at about RM5.58 million (US$1.37 million). The company also cited Malaysia RE policy targets and plans for 25-year operations.

thestarphoenix.com4 min
AUG 12
$AEHRMed

Aehr Test Systems: Aehr Receives $22 Million Follow-On Order for AI Processor Wafer-Level Burn-In Systems

Aehr Test Systems (NASDAQ:AEHR) said it received a $22 million follow-on production order from its lead wafer-level AI processor customer. The order includes multiple FOX-XP wafer-level burn-in systems plus FOX WaferPak contactors and auto aligners, testing nine 300mm wafers per system. Aehr expects shipment over six months for installation in Taiwan.

finanznachrichten.de4 min
AUG 12
$ANNXMedAI 8/10

Annexon Biosciences: Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (Nasdaq: ANNX) reported Q2 2026 results and clinical updates. It said tanruprubart GBS data support a Q4 2026 BLA submission, and vonaprument GA Phase 3 ARCHER II is on track with a Month 15 endpoint in Q4 2026 and Month 24 in Q3 2027. Cash was $209.2M at June 30, 2026; net loss was $55.3M. It also secured a $200M credit facility.

finanznachrichten.de7 min
AUG 12
$BKRMed

Baker Hughes wins KOC contract Ahmadi Innovation Valley project

Baker Hughes said it won a multi-year contract from Kuwait Oil Company (KOC) for the Ahmadi Innovation Valley project. The deal will fund a dedicated research and technology development centre to evaluate and deploy solutions for upstream oil and gas, including digital tools and AI automation to improve recovery, cut costs, reduce water and power use. Related KOC awards also went to SLB and Halliburton.

offshore-technology.com4 min